Brigitte C Vanle1, Virginia R Florang1, Daryl J Murry1, Arturo L Aguirre1, Jonathan A Doorn2. 1. Department of Pharmaceutical Sciences and Experimental Therapeutics, Division of Medicinal and Natural Products Chemistry, College of Pharmacy, The University of Iowa, 115 South Grand Ave, Iowa City, IA 52242-1112, United States. 2. Department of Pharmaceutical Sciences and Experimental Therapeutics, Division of Medicinal and Natural Products Chemistry, College of Pharmacy, The University of Iowa, 115 South Grand Ave, Iowa City, IA 52242-1112, United States. Electronic address: jonathan-doorn@uiowa.edu.
Abstract
BACKGROUND: The aldehyde metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde (DOPAL) is an endogenous neurotoxin implicated in Parkinson's Disease. Elucidating protein targets of DOPAL is essential in understanding it's pathology. The enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a target of DOPAL. METHODS: GAPDH activity was measured via reduction of NAD+ cofactor (340 nm). Protein aggregation was assessed with SDS-PAGE methods and specific modification via chemical probes. RESULTS: Low micromolar levels of DOPAL caused extensive GAPDH aggregation and irreversibly inhibited enzyme activity. The inactivation of GAPDH was dependent on both the catechol and aldehyde moieties of DOPAL. It is suggested that Cys are modified and oxidized by DOPAL. CONCLUSIONS: The mechanism by which DOPAL modifies GAPDH can serve as a mechanistic explanation to the pathological events in Parkinson's Disease.
BACKGROUND: The aldehyde metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde (DOPAL) is an endogenous neurotoxin implicated in Parkinson's Disease. Elucidating protein targets of DOPAL is essential in understanding it's pathology. The enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a target of DOPAL. METHODS:GAPDH activity was measured via reduction of NAD+ cofactor (340 nm). Protein aggregation was assessed with SDS-PAGE methods and specific modification via chemical probes. RESULTS: Low micromolar levels of DOPAL caused extensive GAPDH aggregation and irreversibly inhibited enzyme activity. The inactivation of GAPDH was dependent on both the catechol and aldehyde moieties of DOPAL. It is suggested that Cys are modified and oxidized by DOPAL. CONCLUSIONS: The mechanism by which DOPAL modifies GAPDH can serve as a mechanistic explanation to the pathological events in Parkinson's Disease.
Authors: William J Burke; Vijaya B Kumar; Neeraj Pandey; W Michael Panneton; Qi Gan; Mark W Franko; Mark O'Dell; Shu Wen Li; Yi Pan; Hyung D Chung; James E Galvin Journal: Acta Neuropathol Date: 2007-10-27 Impact factor: 17.088
Authors: Judit Oláh; Natália Tokési; Orsolya Vincze; István Horváth; Attila Lehotzky; Anna Erdei; Emília Szájli; Katalin F Medzihradszky; Ferenc Orosz; Gábor G Kovács; Judit Ovádi Journal: FEBS Lett Date: 2006-09-27 Impact factor: 4.124
Authors: Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer Journal: J Biol Chem Date: 2015-09-17 Impact factor: 5.157
Authors: William J Burke; Shu Wen Li; Hyung D Chung; David A Ruggiero; Bruce S Kristal; Eugene M Johnson; Patricia Lampe; Vijaya B Kumar; Mark Franko; Evelyn A Williams; Daniel S Zahm Journal: Neurotoxicology Date: 2004-01 Impact factor: 4.294
Authors: Margaret-Ann M Nelson; Zachariah J Builta; T Blake Monroe; Jonathan A Doorn; Ethan J Anderson Journal: Amino Acids Date: 2018-09-06 Impact factor: 3.520
Authors: Diego Castillo-Barnes; Javier Ramírez; Fermín Segovia; Francisco J Martínez-Murcia; Diego Salas-Gonzalez; Juan M Górriz Journal: Front Neuroinform Date: 2018-08-14 Impact factor: 4.081
Authors: B S Cagle; M L Sturgeon; J B O'Brien; J C Wilkinson; R A Cornell; D L Roman; J A Doorn Journal: Toxicol In Vitro Date: 2021-07-05 Impact factor: 3.685